Novocure Ltd (NVCR) vs Xeris Biopharma Holdings, Inc. (XERS)
A side-by-side comparison of Novocure Ltd and Xeris Biopharma Holdings, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NVCR
Novocure Ltd
$15.16HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
XERS
Xeris Biopharma Holdings, Inc.
$10.03HealthcareDelayed quote: Oct 6, 2026, 3:10 PM EDT
Total return — NVCR vs XERS
growth of $100 · dividends reinvested · last 8yNVCR -51.1% (-8.6%/yr)XERS -49.9% (-8.3%/yr)XERS compounded faster over this window
NVCR XERS
NVCR vs XERS: by the numbers
- •NVCR is the larger company ($1.76B vs $1.73B market cap).
- •Both run net losses; XERS's is the smaller (-5.12% vs -21.25% net margin).
- •XERS grew revenue faster over the past five years (58.33% vs 5.12% CAGR).
Metrics side by side
Valuation
| Metric | NVCR | XERS |
|---|---|---|
| P/S ratio | 2.52 | 5.16 |
| P/B ratio | 5.22 | N/A |
| EV / EBITDA | N/A | 38.70 |
| FCF yield | N/A | 3.20% |
Profitability
| Metric | NVCR | XERS |
|---|---|---|
| Gross margin | 76.13% | 83.34% |
| Operating margin | -22.08% | 10.91% |
| Net margin | -21.25% | -5.12% |
| ROE | -43.94% | N/A |
| ROIC | -26.88% | 12.79% |
Growth (annualized)
| Metric | NVCR | XERS |
|---|---|---|
| Revenue CAGR (5Y) | 5.12% | 58.33% |
| Total return CAGR (5Y) | -32.71% | 33.72% |
Frequently asked
- Which has grown faster, NVCR or XERS?
- Over the past five years, XERS grew revenue faster — NVCR at a 5.12% CAGR versus XERS at 58.33%.
- How have NVCR and XERS total returns compared?
- Over the past 5 years, NVCR delivered -32.71% and XERS delivered 33.72% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Novocure ROEXeris Biopharma ROENovocure operating marginXeris Biopharma operating marginNovocure revenue growthXeris Biopharma revenue growthNovocure free cash flowXeris Biopharma free cash flow
Novocure & Xeris Biopharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.